Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
78
TMDX Quote, Financials, Valuation and Earnings
Last price:
$145.31
Seasonality move
:
29.19%
Day range:
$128.00 - $135.41
52-week range:
$62.07 - $156.00
Dividend yield:
0%
P/E ratio:
27.71x
P/S ratio:
9.01x
P/B ratio:
9.72x
Volume:
825.1K
Avg. volume:
799.9K
1-year change:
82.44%
Market cap:
$4.6B
Revenue:
$605.5M
EPS (TTM):
$4.86
Analysts' Opinion
-
Consensus RatingTransMedics Group, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $157.55, TransMedics Group, Inc. has an estimated upside of 17.07% from its current price of $134.57.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $115.00 representing 14.54% downside risk from its current price of $134.57.
Fair Value
-
According to the consensus of 10 analysts, TransMedics Group, Inc. has 17.07% upside to fair value with a price target of $157.55 per share.
TMDX vs. S&P 500
-
Over the past 5 trading days, TransMedics Group, Inc. has overperformed the S&P 500 by 1.28% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
TransMedics Group, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
TransMedics Group, Inc. has grown year-over-year revenues for 17 quarters straight. In the most recent quarter TransMedics Group, Inc. reported revenues of $160.8M.
Earnings Growth
-
TransMedics Group, Inc. has grown year-over-year earnings for 9 quarters straight. In the most recent quarter TransMedics Group, Inc. reported earnings per share of $2.58.
Enterprise value:
4.6B
EV / Invested capital:
4.67x
Price / LTM sales:
9.01x
EV / EBIT:
42.64x
EV / Revenue:
7.65x
PEG ratio (5yr expected):
0.07x
EV / Free cash flow:
34.66x
Price / Operating cash flow:
40.84x
Enterprise value / EBITDA:
34.10x
Gross Profit (TTM):
$362.5M
Return On Assets:
20.59%
Net Income Margin (TTM):
31.43%
Return On Equity:
57.97%
Return On Invested Capital:
22.46%
Operating Margin:
13.23%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $241.6M | $441.5M | $605.5M | $121.6M | $160.8M | |
| Gross Profit | $154.1M | $261.8M | $362.5M | $72M | $93.4M | |
| Operating Income | -$1.5M | $37.5M | $108.6M | $8.6M | $21.3M | |
| EBITDA | $7.2M | $57.4M | $135.8M | $14.3M | $28.7M | |
| Diluted EPS | -$0.77 | $1.01 | $4.86 | $0.19 | $2.58 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $118.7M | $252.3M | $510.7M | $497.2M | $637.8M | |
| Total Assets | $134.9M | $277.1M | $706M | $828.4M | $1.1B | |
| Current Liabilities | $23.2M | $23.7M | $54.9M | $59.9M | $89.3M | |
| Total Liabilities | $67M | $89.8M | $568.8M | $599.8M | $645.6M | |
| Total Equity | $67.9M | $187.4M | $137.2M | $228.6M | $473.1M | |
| Total Debt | $43.8M | $66.1M | $513.9M | $515.6M | $516M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$13M | $48.8M | $192.8M | $19.7M | $34.5M | |
| Cash From Investing | -$194M | -$129.3M | -$59.3M | -$13.6M | -$15.5M | |
| Cash From Financing | $400.4M | $22.9M | $16.9M | $1.2M | $3.1M | |
| Free Cash Flow | -$192.1M | -$80.9M | $133.6M | $6.1M | $19M | |
TMDX
Sector
Market Cap
$4.6B
$25.8M
Price % of 52-Week High
86.26%
50.24%
Dividend Yield
0%
0%
Shareholder Yield
-0.41%
-1.64%
1-Year Price Total Return
82.44%
-18.88%
Beta (5-Year)
2.059
0.496
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$134.41
200-day SMA
Buy
Level
$125.41
Bollinger Bands (100)
Buy
Level
120.06 - 138.9
Chaikin Money Flow
Buy
Level
1.3M
20-day SMA
Buy
Level
$134.01
Relative Strength Index (RSI14)
Buy
Level
50.39
ADX Line
Buy
Level
17.53
Williams %R
Neutral
Level
-58.4118
50-day SMA
Buy
Level
$132.85
MACD (12, 26)
Buy
Level
36.69
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
1.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.9657)
Sell
CA Score
(Annual)
Level (-0.3594)
Sell
Beneish M-Score
(Annual)
Level (-1.4955)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-0.8871)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.
Stock Forecast FAQ
In the current month, TMDX has received 7 Buy ratings 3 Hold ratings, and 0 Sell ratings. The TMDX average analyst price target in the past 3 months is $157.55.
-
Where Will TransMedics Group, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that TransMedics Group, Inc. share price will rise to $157.55 per share over the next 12 months.
-
What Do Analysts Say About TransMedics Group, Inc.?
Analysts are divided on their view about TransMedics Group, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that TransMedics Group, Inc. is a Sell and believe this share price will drop from its current level to $115.00.
-
What Is TransMedics Group, Inc.'s Price Target?
The price target for TransMedics Group, Inc. over the next 1-year time period is forecast to be $157.55 according to 10 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is TMDX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for TransMedics Group, Inc. is a Buy. 7 of 10 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of TMDX?
You can purchase shares of TransMedics Group, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase TransMedics Group, Inc. shares.
-
What Is The TransMedics Group, Inc. Share Price Today?
TransMedics Group, Inc. was last trading at $145.31 per share. This represents the most recent stock quote for TransMedics Group, Inc.. Yesterday, TransMedics Group, Inc. closed at $134.57 per share.
-
How To Buy TransMedics Group, Inc. Stock Online?
In order to purchase TransMedics Group, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get TMDX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
TMDX
Sector
P/E ratio
27.71x
23.44x
PEG ratio
0.07x
-0.01x
P/B ratio
9.72x
1.81x
Price / LTM sales
9.01x
1.56x
Growth Metrics
TMDX
Sector
Revenue growth
32.18%
3.27%
Earnings growth
1223.11%
9.66%
Revenue (5-year growth)
88.21%
6.43%
Earnings forecast
$0.37
-$0.20
Profitability
TMDX
Sector
Profitability FY 2025
$362.6M
$2.3M
Return on invested capital
22.46%
-33.49%
Return on assets
20.59%
-29.74%
Return on equity
57.97%
-39.33%
Earnings Date
Last Earnings Date
Feb
24
Next Earnings Date
May
7
Estimated Next Earnings Date
May
26
Balance Sheet
TMDX
Sector
Total cash
$488.4M
$24.2M
Short term investments
--
$23.8M
Total assets
$1.1B
$71.1M
Long term debt
$516M
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
